You are here: Home » Companies » News
Business Standard

Aurobindo named in a lawsuit for selling adulterated irbesartan products

In October, Aurobindo Pharma announced a voluntary recall of 22 batches of irbesartan due to the detection of trace amounts of NDEA

BS Reporter  |  Hyderabad 

Aurobindo Pharma
Photo: Shutterstock

Hyderabad-based drug major Limited has been named in a class action lawsuit in the US for contamination of its active ingredient (API) used in the treatment of high blood pressure.

The lawsuit was filed in the against and also the US-based pharma company ScieGen Pharmaceuticals, which used Aurobindo's API to make its blood pressure lowering product, besides the distributor Westminster Pharmaceuticals and the US retail supply chain Walmart.

Aurobindo scrip lost as much as Rs 22 or down close to 3 per cent on Tuesday after touching a new 52-week high of Rs 830 yesterday.

The latest lawsuit is a part of growing litigation against the makers and distributors of sartan-based blood pressure lowering drugs in the US. In July, US Food and Drug Administration (US FDA) initiated a largest-ever Class I recall of valsartan-based blood pressure lowering tablets sold by Solco Healthcare, Major Pharmaceuticals and Teva after it was found that the valsartan active ingredient (API) contained a known carcinogenic impurity called N-nitrosodimethylamine (NDMA), which is expected to show up in sartan-based drugs in certain manufacturing methods.

ALSO READ: Aurobindo Pharma hits 52-week high; up 56% in six months

Earlier, the European Medicines Agency announced that it had started reviewing medicines with valsartan ingredient supplied by Chinese company Zhejiang Huahai Pharmaceuticals, which is currently facing similar lawsuits in Missouri, New Jersey, Illinois and New York in the USA.

In October, announced a voluntary recall of 22 batches of due to the detection of trace amounts of NDEA (NNitrosodiethylamine), a human carcinogenic impurity. In August, another Hyderabad-based drug company, Hetero Drugs, announced a recall of around 1.6 million bottles of valsartan tablets from the US market for similar reasons.

Recently, US generic drug major Mylan initiated a voluntary recall of valsartan products after the company reported that NDEA was found in some of the APIs made at one of its Indian plants and which Teva also used to make blood pressure lowering products.

The lawsuit filed against the and distributors said consumers were injured by paying the full purchase price of their medications containing the and by paying for incidental medical expenses and mentioned other grounds.


ALSO READ: Improving margins, reducing debt key challenges for Aurobindo Pharma

Under American law, a group of people with the same or similar injuries caused by the same product or action can sue the defendant as a group in a class action lawsuit. The class action lawsuits often reach settlements involving payment of compensation by the defendant

First Published: Wed, December 05 2018. 15:49 IST
RECOMMENDED FOR YOU